{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T01:54:59Z","timestamp":1767664499702},"reference-count":25,"publisher":"Royal College of Psychiatrists","issue":"1","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":7671,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1997,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Approximately 5\u201310% of Caucasians (poor metabolisers) show impaired metabolism of at least 20 therapeutically important drugs, including a number of commonly used antipsychotic agents, because they lack the cytochrome p450 enzyme <jats:italic>CYP2D6<\/jats:italic>. The molecular basis of this defect is now well understood and simple genotyping tests using the polymerase chain reaction (PCR) have been developed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>To determine whether poor metabolisers are more susceptible to acute dystonic reactions and chronic movement disorders associated with the administration of antipsychotic drugs, we determined <jats:italic>CYP2D6<\/jats:italic> genotypes in a group of 76 schizophrenics using previously described methods involving PCR and restriction fragment length polymorphism analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was no difference in genotype frequencies between the schizophrenics and a normal control population, suggesting that <jats:italic>CYP2D6<\/jats:italic> genotype was not a factor in determining susceptibility to the disease. However, four of the five poor metabolisers compared with 44% of the remaining subjects were suffering from a movement disorder at the time of the study, although because of the small number of poor metabolisers in the group the difference was not statistically significant. Poor metabolisers were not more likely to suffer an acute dystonic reaction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p><jats:italic>CYP2D6<\/jats:italic> genotype is not a determinant of susceptibility to acute dystonic reactions but may be a contributory factor in antipsychotic drug-induced movement disorders including tardive dyskinesia.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.170.1.23","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T05:36:56Z","timestamp":1224049016000},"page":"23-26","source":"Crossref","is-referenced-by-count":74,"title":["Antipsychotic drug-induced movement disorders in schizophrenics in relation to <i>CYP2D6<\/i> genotype"],"prefix":"10.1192","volume":"170","author":[{"given":"Martin","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann K.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Blennerhassett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol","family":"Ferrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Idle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000145726_ref25","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.22"},{"key":"S0007125000145726_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-6618(05)80063-5"},{"key":"S0007125000145726_ref5","first-page":"545","article-title":"Debrisoquine\/ sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population","volume":"10","author":"Broly","year":"1991","journal-title":"DMA and Cell Biology"},{"key":"S0007125000145726_ref18","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(90)90741-G"},{"key":"S0007125000145726_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90111-3"},{"key":"S0007125000145726_ref14","first-page":"534","volume-title":"Assessment Manual for Psychopharmacology","year":"1976"},{"key":"S0007125000145726_ref8","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.2"},{"key":"S0007125000145726_ref11","volume-title":"Genetic Factors in Drug Therapy","author":"Evans","year":"1993"},{"key":"S0007125000145726_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(92)90140-2"},{"key":"S0007125000145726_ref3","volume-title":"Statistical Methods in Medical Research","author":"Armitage","year":"1967"},{"key":"S0007125000145726_ref4","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199506000-00010"},{"key":"S0007125000145726_ref19","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1982.04290040052008"},{"key":"S0007125000145726_ref10","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199110000-00006"},{"key":"S0007125000145726_ref2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1967"},{"key":"S0007125000145726_ref13","first-page":"378","article-title":"Adverse effects of psychotrophic drugs","volume":"1","author":"Grohman","year":"1983","journal-title":"Clinical Psychopharmacology"},{"key":"S0007125000145726_ref1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00316090"},{"key":"S0007125000145726_ref9","first-page":"78","article-title":"Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population","volume":"46","author":"Dahl-Puustian","year":"1989","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"S0007125000145726_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93266-P"},{"key":"S0007125000145726_ref24","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/13.6.1035"},{"key":"S0007125000145726_ref17","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199204000-00003"},{"key":"S0007125000145726_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92086-W"},{"key":"S0007125000145726_ref23","first-page":"257","article-title":"Critical analysis of the disability of Parkinsons disease","volume":"5","author":"Webster","year":"1968","journal-title":"Modem Treatment"},{"key":"S0007125000145726_ref7","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199304000-00001"},{"key":"S0007125000145726_ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1992.tb03281.x"},{"key":"S0007125000145726_ref12","doi-asserted-by":"publisher","DOI":"10.1038\/347773a0"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000145726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T19:38:48Z","timestamp":1557689928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000145726\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1997,1]]}},"alternative-id":["S0007125000145726"],"URL":"https:\/\/doi.org\/10.1192\/bjp.170.1.23","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,1]]}}}